Organic compounds -- part of the class 532-570 series – Organic compounds – Oxygen containing
Reexamination Certificate
2006-11-01
2008-12-23
Seaman, D. Margaret (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Oxygen containing
C549S374000, C549S510000
Reexamination Certificate
active
07468462
ABSTRACT:
The present invention is directed to novel compounds according to formulaewherein R1, R2, R3and R4are as defined herein. The invention also discloses methods of preparation, pharmaceutical compositions, and methods of disease treatment utilizing pharmaceutical compositions comprising these compounds. The compounds of this invention are novel therapeutic agents for the treatment of cancer, diabetes, metabolic diseases and skin disorders in mammalian subjects. These compounds are also useful modulators of gene expression. They exert their activity by interfering with certain cellular signal transduction cascades. The compounds of the invention are thus also useful for regulating cell differentiation and cell cycle processes that are controlled or regulated by various hormones or cytokines. The invention also discloses pharmaceutical compositions and methods of treatment of disease in mammals.
REFERENCES:
patent: 6825233 (2004-11-01), Ericsson et al.
patent: 6844466 (2005-01-01), Belloni et al.
Pirrung et al. STN Accession No. 1995:466019; Document No. 123:169582; Abstract of Journal of Organic Chemistry, 1995, 60(7), 2112-24.
Okajima et al. STN Accession No. 1990:497481: Document No. 113:97481; Abstract of Journal of Heterocyclic Chemistry, 1990, 567-574.
Winternitz et al. STN Accession No. 1950:14863; Document No. 44:14863; Abstract of Bulletin de la Societe Chimique de France (1949) 713-722.
Rolewski S. Wikipedia, Abstact of “Clinical review: topical retinoids.”. Dermatol Nurs 15 (5): 447-50, 459-65, 2003.
Muccio et al., “Conformationally Defined 6-s-trans-Retinoic Acid Analogs. 3. Structure-Activity Relationship for Nuclear Receptor Binding, Transcriptional Activity, and Cancer Chemopreventive Activity,”J. Med. Chem., 39:3625-3635, American Chemical Society (1996).
Zacheis et al., “Heteroarotinoids Inhibit head and Neck Cancer Cell Lines in Vitro and in Vivo through Both RAR and RXR Retinoic Acid Receptors,”J. med. Chem., 42:4434-4445, American Chemical Society (1999).
Auspex Pharmaceuticals
Bennett Dennis A.
Chandrakumar Nizal S
Seaman D. Margaret
Sertie Michael
LandOfFree
Therapeutic agents for the treatment of cancer, metabolic... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic agents for the treatment of cancer, metabolic..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic agents for the treatment of cancer, metabolic... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4050086